Institutul De Psihiatrie Socola Iasi

Running trials

• Recruiting

  Randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of Roluperidone in adults with negative symptoms of schizophrenia

  2026-525925-19-00· Phase 3· Source

• Recruiting

  Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

  NCT07288333· Phase 2· Source

• Recruiting

  A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Phase 3· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

  NCT06887192· Phase 2· Source

• Recruiting

  NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

  NCT07105098· Phase 3· Source

• Recruiting

  A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

  NCT06929273· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

  NCT06976216· Phase 3· Source

• Recruiting

  NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

  NCT07114874· Phase 3· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Schizophrenia5 recruiting
• Alzheimer disease4 recruiting
• Bipolar disorder1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A study to assess the efficacy and safety of lumateperone in patients with Bipolar Mania

  2024-513037-20-00· Phase 3· Source

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia

  2024-511057-22-00· Phase 3· Source

• Completed

  Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

  2022-502233-25-00· Phase 3· Source

• Completed

  Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

  NCT05110157· Phase 3· Source